1 week Ago
Using iPS cells generated from a patient with a myeloid neoplasm caused by a rare chromosomal rearrangement between the MECOM and MYC genes, a team of researchers led by Associate Professor Yoshinori Yoshida and Clinical Assistant Professor Kazuhisa Chonabayashi (Department of Growth and Differentiation) successfully modeled the cancer to gain a better understanding of its pathogenic mechanisms and test potential drug therapies. There are many causes for cancers, but a primary means for their development is the rearrangement of chromosomes that allows cancer-causing genes to hijack enhancer elements from other genes to increase their expression aberrantly. For example, recurrent rearrangements on chromosome 3 (inv(3)(q21.
3q26.2) or t(3;3)(q21.3;q26.
2)) place a GATA2 enhancer close to the MECOM (EVI1) promoter to drive hematological malignancies by aberrantly enhancing MECOM gene expression. More recently, a specific type of leukemia, known as myelodysplastic syndromes (MDS)/ acute myeloid leukemia (AML) with atypical 3q26 rearrangements including t(3;8)(q26.2;q24), in which chromosomal changes also result in abnormally high expression of MECOM was characterized.
While these chromosomal rearrangements are rare, the resulting cancer has a poor prognosis with a median survival of only about six months and, as such, was designated as a new category of AML with MECOM rearrangement by the World Health Organization in 2022. To gain insights into this newly categorized disease and identify potential therapeutic strategies, the research team successfully established iPS cells from an MDS patient with t(3;8)(q26.2;q24) (MDS-iPSCs), which showed the same chromosomal abnormalities as cells originally collected from the patient.
The research results are published in the British Journal of Haematology . Specifically, chromosomal breakpoints were identified upstream of the MECOM (MDS1-EVI1 and EVI1) promoters on 3q26.2 and upstream of the MYC super-enhancer on 8q24.
They subsequently differentiated these MDS-iPSCs into hematopoietic progenitor cells (MDS-HPCs) as an MDS disease model. As expected, MDS-HPCs displayed leukemic morphology and showed defects for differentiating into myeloid (granulocytes and monocytes) and erythroid (red blood cells) lineages. Consistently, gene expression analysis by RNA sequencing revealed many dysregulated genes, with reduced expression of numerous factors critical for hematopoietic differentiation and, conversely, the expression of many regulators crucial to HSC maintenance enhanced in MDS-HPCs compared to HPCs generated from isogenic normal iPS cells.
Notably, MDS-HPCs displayed an AML-like gene expression signature. Furthermore, MECOM gene expression was increased dramatically in MDS-HPCs, consistent with the hypothesized causal role in the disease. Epigenetic analyses further indicated that the activity of the MDS1-EVI1 and EVI1 promoters was markedly increased in MDS-HPCs, consistent with enhanced MECOM expression in this patient's HPCs due to the translocation of the MYC super-enhancer.
Because BRD4, a member of the bromodomain and extraterminal (BET) protein family, accumulates at super-enhancers, the researchers speculated that its inhibition could suppress the expression of cancer-causing genes. To test this hypothesis, they treated MDS-HPCs with JQ1, a BRD4 inhibitor, and monitored MECOM expression. While JQ1 treatment did not affect control HPCs, it significantly lowered MECOM expression in MDS-HPCs.
Consistent with this, a fluorescent report-based assay revealed that JQ1 effectively reduces gene expression from the EVI1 locus. Most importantly, however, JQ1 treatment led to increased cell death of MDS-HPCs in a dose-dependent manner but did not affect control HPCs, thus demonstrating its therapeutic potential against MDS/AML. Altogether, this work demonstrates again the power of iPS cell technology for modeling human diseases and reinforces it as an effective means of testing promising therapies that may be useful in clinics as treatments and cures.
More information: Momoko Nakamura et al, Modelling and drug targeting of a myeloid neoplasm with atypical 3q26/MECOM rearrangement using patient‐specific iPSCs, British Journal of Haematology (2024). DOI: 10.1111/bjh.
19720.
